Alto Neuroscience (NYSE:ANRO) Reaches New 52-Week High – What’s Next?

Alto Neuroscience, Inc. (NYSE:ANRO)’s stock price reached a new 52-week high during trading on Monday . The company traded as high as $21.70 and last traded at $21.22, with a volume of 90206 shares changing hands. The stock had previously closed at $20.76.

Analyst Ratings Changes

Several equities analysts have recently commented on ANRO shares. Weiss Ratings restated a “sell (e+)” rating on shares of Alto Neuroscience in a research report on Monday, December 29th. Jefferies Financial Group increased their target price on Alto Neuroscience from $15.00 to $25.00 and gave the stock a “buy” rating in a research report on Wednesday, November 12th. Robert W. Baird lifted their target price on Alto Neuroscience from $16.00 to $22.00 and gave the company an “outperform” rating in a research note on Thursday, November 13th. Wall Street Zen upgraded Alto Neuroscience from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. Finally, Chardan Capital increased their price objective on shares of Alto Neuroscience from $15.00 to $30.00 and gave the company a “buy” rating in a report on Monday, January 5th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $26.50.

Alto Neuroscience Trading Up 2.5%

The company has a debt-to-equity ratio of 0.20, a current ratio of 15.42 and a quick ratio of 15.42. The stock has a 50-day moving average price of $17.37 and a two-hundred day moving average price of $12.44. The stock has a market cap of $660.86 million, a PE ratio of -9.29 and a beta of 2.51.

Institutional Trading of Alto Neuroscience

Large investors have recently added to or reduced their stakes in the company. XTX Topco Ltd raised its holdings in shares of Alto Neuroscience by 32.2% during the 4th quarter. XTX Topco Ltd now owns 20,824 shares of the company’s stock worth $371,000 after acquiring an additional 5,078 shares in the last quarter. Ikarian Capital LLC grew its holdings in shares of Alto Neuroscience by 368.2% in the fourth quarter. Ikarian Capital LLC now owns 515,000 shares of the company’s stock valued at $9,167,000 after purchasing an additional 405,000 shares in the last quarter. Vestal Point Capital LP increased its position in Alto Neuroscience by 161.6% in the fourth quarter. Vestal Point Capital LP now owns 2,485,000 shares of the company’s stock worth $44,233,000 after purchasing an additional 1,535,000 shares during the last quarter. Wellington Management Group LLP bought a new stake in Alto Neuroscience in the fourth quarter worth $1,228,000. Finally, Perceptive Advisors LLC raised its stake in Alto Neuroscience by 1,048.5% during the fourth quarter. Perceptive Advisors LLC now owns 1,784,393 shares of the company’s stock valued at $31,762,000 after purchasing an additional 1,629,027 shares in the last quarter.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.